Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 13;184(1):6.
doi: 10.1007/s00431-024-05864-1.

Incidence of severe and non-severe SARS-CoV-2 infections in children and adolescents: a population-based cohort study using six healthcare databases from Italy, Spain, and Norway

Carlos E Durán  1 , Fabio Riefolo  2 , Rosa Gini  3 , Elisa Barbieri  4 , Davide Messina  3 , Patricia Garcia  5 , Mar Martin  5 , Felipe Villalobos  6 , Luca Stona  7 , Juan-José Carreras  8 , Arantxa Urchueguía  8 , Elisa Correcher-Martínez  8 , Jing Zhao  9 , Angela Lupattelli  9 , Hedvig Nordeng  9 , Miriam Sturkenboom  10
Affiliations

Incidence of severe and non-severe SARS-CoV-2 infections in children and adolescents: a population-based cohort study using six healthcare databases from Italy, Spain, and Norway

Carlos E Durán et al. Eur J Pediatr. .

Abstract

We aim to estimate the incidence rates (IRs) of SARS-CoV-2 infections stratified by disease severity and comorbidities in pediatric population and to describe the COVID-19 vaccination coverage in children with and without comorbidities. A population-based cohort study was conducted in 6 electronic healthcare records databases from Italy, Spain, and Norway. The study lasted from 1 January 2020 to the latest databases' available data in each site, i.e., in Italian ARS Tuscany and PEDIANET: December 2021, in Spanish BIFAP: February 2022; SIDIAP: June 2022, and VID: December 2021. Finally, in Norwegian Health Registries: December 2021. Children and adolescents were included and stratified into three age categories (< 5, 5- < 12, and 12- < 18 years old). IRs (95% confidence intervals) per 100 person-years (PY) for non-severe (positive SARS-CoV-2 test or diagnosis without hospitalization) and severe COVID-19 (hospitalization, intensive care unit admission, and death after COVID-19) are reported. The cumulative COVID-19 vaccination rollout was stratified by population with and without comorbidities. The study population comprised 5,654,040 individuals < 18 years of age (51% females) across the six European databases (median age: 6 years), with 1.4 to 8.5% of them having at least one at-risk comorbidity for severe COVID-19. Incidence rates of severe COVID-19 were low (0-1 per 100 PY) but 3 to 4 times higher among children and adolescents with comorbidities during Omicron BA.1-2 wave in December 2021-January 2022. Percentages of vaccination rollout in the general population were between 13% in PEDIANET-IT and 64% in BIFAP-ICU-ES. In ARS-IT and SIDIAP-IT, vaccination rate in children with comorbidities was slightly lower than that in the general population.

Conclusion: Severe COVID-19 was rare across databases, but up to 3 to 4 times higher in children with comorbidities during the predominance of Omicron BA.1-2 variant in winter 2021-2022. COVID-19 vaccination coverage was slightly lower in children with comorbidities in ARS (Tuscany) and SIDIAP (Catalonia) data sources. Our findings will inform future public policies aimed to protect the pediatric population, both within these countries and globally.

What is known: • Pediatric population is susceptible to SARS-CoV-2 infection. • COVID-19 severity rates in children vary across study settings and context.

What is new: • This study confirms the low severity rates of COVID-19 in the pediatric population based on a large cohort of children and adolescents residing in Spain, Italy, and Norway. • Incidence of severe COVID-19 in children and adolescents with comorbidities was up to 3 to 4 times higher than in the general pediatric population during the SARS-CoV-2 high transmission wave of Omicron BA.1-2 variant in winter 2021-2022 in Italy and Spain.

Keywords: COVID-19; Incidence rate; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declarations Ethics approval Most data partners that provided data for the herein-presented results had passed the local ethical review process for the whole COVID-19 Vaccine Monitor study (EUPAS42467); Norwegian data (NHR): Regional Committee for Research Ethics (approval number 155294/REK Nord) and the Data Protection Officer at the University of Oslo (approval number 523275); Valencian data (VID): Comité Ético de Investigación con Medicamentos del Hospital General Universitario de Elche (approval number: PI-90/2021); Catalonian data (SIDIAP): Comitè Ètic d'Investigació amb medicaments (CEIm) de l'IDIAP Jordi Gol (approval number: 21/199-PCV); and BIFAP (several Spanish regions): Comité de Ética de la Investigación con Medicamentos del Hospital Universitario de la Princesa and Comité Científico de BIFAP (approval number: CEIm 14/21). There was no need of ethical committee approval for Italian databases (ARS and PEDIANET). This research adhered to the rules and principles of the European Network of Centers of Pharmacoepidemiology and Pharmacovigilance (ENCePP) Code of Conduct. Consent to participate This research was conducted using secondary heathcare data. Informed consent to participate was not obtained. The whole COVID-19 Vaccine Monitor study (EUPAS42467) was conducted following the ENCePP Code of Conduct. Competing interests The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Shao W, Zhang W, Fang X et al (2022) Challenges of SARS-CoV-2 Omicron variant and appropriate countermeasures. J Microbiol Immunol Infect 55(3):387–394. https://doi.org/10.1016/j.jmii.2022.03.007 - DOI - PubMed - PMC
    1. Hu FH, Jia YJ, Zhao DY et al (2023) Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients. Clin Microbiol Infect 29(7):835–844. https://doi.org/10.1016/j.cmi.2023.03.017 - DOI - PubMed - PMC
    1. Chun JY, Jeong H, Kim Y (2022) Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529). BMC Med 20(1):451. https://doi.org/10.1186/s12916-022-02655-z - DOI - PubMed - PMC
    1. Whittaker R, Greve-Isdahl M, Bøås H et al (2022) COVID-19 Hospitalization among children <18 years by variant wave in Norway. Pediatrics 150(3):e2022057564. https://doi.org/10.1542/peds.2022-057564 - DOI - PubMed
    1. Butt AA, Dargham SR, Loka S et al (2022) Coronavirus Disease 2019 disease severity in children infected with the omicron variant. Clin Infect Dis 75(1):e361–e367. https://doi.org/10.1093/cid/ciac275 - DOI - PubMed

Substances

LinkOut - more resources